Filing Flows › Alkermes (ALKS) › R&D spending
Alkermes (ALKS) R&D spending by quarter
Alkermes' R&D spending was $121M in Q3 2026 (third quarter 2026), +7% from Q2 2026. Over the last 7 quarters it ranged from $71.8M (Q1 2025) to $121M (Q3 2026).
| Quarter | R&D spending | Q/Q | Y/Y |
|---|---|---|---|
| Q3 2026 | $121M | +7% | +48% |
| Q2 2026 | $113M | +9% | +46% |
| Q1 2026 | $103M | +11% | +44% |
| Q4 2025 | $93.0M | +14% | — |
| Q3 2025 | $81.7M | +6% | — |
| Q2 2025 | $77.4M | +8% | — |
| Q1 2025 | $71.8M | — | — |
Q3 2026 at a glance
Alkermes, Q3 2026: revenue $480M (+22% year over year), operating margin 7.5%, net earnings $16.3M, operating cash flow $93.5M. The chart follows the revenue to costs, profit and cash.
Questions
What is Alkermes' R&D spending?
Alkermes' R&D spending was $121M in Q3 2026 (third quarter 2026), +7% from Q2 2026.
How has Alkermes' R&D spending changed?
Over the last 7 quarters it ranged from $71.8M (Q1 2025) to $121M (Q3 2026).